1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd.

XTLB.TA
XTL Biopharmaceuticals Ltd.IL flagTel Aviv Stock Exchange
1.70
ILA
-0.10
- -
16.09MMarket Cap
XTL Biopharmaceuticals Ltd.
XTLB.TA
(Tel Aviv Stock Exchange)

Recent

price

1.70

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
0.04
-0.01
-0.01
-0.01
-0.02
-0.01
-0.02
-0.01
- -
0.01
- -
-0.01
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.04
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.39
- -
-0.68
-0.63
-0.63
-0.61
-0.55
-0.54
-0.3
-0.27
-0.27
-0.28
-0.27
-0.26
-0.26
-0.2
-0.25
Book Value per Share
- -
0.02
- -
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
- -
- -
- -
Tangible Book Value per Share
59
113
204
218
224
231
264
274
470
514
514
514
532
545
545
673
545
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-481.6
-481.6
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
3
-1
-1
-1
-4
-3
-4
-3
-1
4
-1
-3
- -
-1
-2
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-227.72
-227.72
Profit Margin (%)
- -
- -
1
2
4
2
4
2
6
8
7
6
6
4
2
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
3
3
9
7
5
5
3
4
7
7
4
5
4
2
5
5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2.61
- -
- -
-0.31
- -
- -
- -
0.19
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
545
881
881
Market Capitalization
1,259
1,314
972

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
2
2
1
Cash, Cash Equivalents & STI
2
2
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
2
2
Payables & Accruals
- -
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.31%
15.68%
144.82%
Free Cash Flow
3.53%
23.53%
136.49%
Net Income, GAAP
-99.32%
-49.53%
-42.37%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Adaptimmune Therapeutics plc (ADAP)
Reneo Pharmaceuticals, Inc. (RPHM)
Newron Pharmaceuticals S.p.A. (NWRN.SW)
Aldeyra Therapeutics, Inc. (ALDX)
Athersys, Inc. (ATHX)
BiomX Inc. (PHGE-UN)
Business
XTL Biopharmaceuticals Ltd. is an Israel-based biopharmaceutical company that acquires, in-licenses, and develops late-stage pharmaceutical product candidates addressing unmet clinical needs in autoimmune diseases and other therapeutic areas; its lead product candidate is hCDR1, a Phase II-ready peptide therapeutic under exclusive license from Yeda Research and Development Company Limited for the treatment of systemic lupus erythematosus and Sjogren’s syndrome; the pipeline also includes recombinant human erythropoietin (rHuEPO) for multiple myeloma and additional clinical-stage compounds identified through systematic validation processes. The company, formerly known as Xenograft Technologies Ltd., was founded in 1993 and is headquartered in Ramat Gan, Israel, with operations focused primarily in Israel and listed on the Nasdaq and Tel Aviv Stock Exchange under the ticker XTLB. In late 2024, XTL Biopharmaceuticals completed the acquisition of The Social Proxy Ltd., an AI-driven web data solutions provider, for $5.8 million in cash and shares, marking a strategic diversification into high-potential technology assets and funded by a $1.5 million private placement; this transaction amended prior terms amid disputes and positions the company to broaden its portfolio beyond biopharmaceuticals.

Company News

APIChat

  • globenewswire.com

    XTL Announces Receipt of Staff Delist Determination from Nasdaq